Min Janice Lu, MD | UniHealth

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Northwestern Memorial Hospital. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

California Medical Board record

Licence C130396 · Current

Licensed to practise in California · since 2014 · expires 2027-09-30 · Peking University Health Science Center.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

Illinois 036164664Licensed Physician And Surgeon · since 2023 · expires 2026-07-31
InactiveNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

Northwestern Memorial HospitalChicago, ILAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Northwestern Medicine, which runs 10 hospitalsHome of Robert H. Lurie Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
Overall rating: 5 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.26 (0.95 to 1.56) · 17,389 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.74 (0.58 to 0.91), Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 1.71 (0 to 5.12) · 2,663 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.15 (0 to 3.19) · 2,766 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.609, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.392, Oct 2024 – Sep 2025

See every measure and the patient survey for Northwestern Memorial Hospital

Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 5 better, 3 the same, 0 worse of 8 measures. Readmissions: 0 better, 8 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Sort by

Every scored measure at Northwestern Memorial Hospital

Pressure ulcer rateComplications and deaths	1.26 (0.95 to 1.56) · 17,389 cases	Worse	Jul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths	0.74 (0.58 to 0.91)	Better	Jul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths	1.71 (0 to 5.12) · 2,663 cases	Better	Jul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths	1.15 (0 to 3.19) · 2,766 cases	Better	Jul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections	0.609	Better	Oct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections	0.392	Better	Oct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths	0.9 (0.25 to 1.55) · 4,931 cases	No different	Jul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths	146.95 (119.26 to 174.63) · 403 cases	No different	Jul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths	2 · 184 cases	None	Jul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths	7.4 · 168 cases	None	Jul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths	10.1 · 163 cases	None	Jul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths	5.7 · 946 cases	None	Jul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths	7.9 · 833 cases	None	Jul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths	8.5 · 513 cases	None	Jul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths	2.2 · 6,861 cases	None	Jul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths	0.15 (0 to 0.3) · 17,912 cases	No different	Jul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths	0.32 (0.17 to 0.48) · 20,121 cases	No different	Jul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths	2.81 (1.6 to 4.02) · 6,294 cases	No different	Jul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths	0.65 (0 to 1.73) · 2,722 cases	No different	Jul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths	1.45 (0.49 to 2.41) · 5,017 cases	No different	Jul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths	2.2 (0.98 to 3.41) · 1,549 cases	No different	Jul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths	3.9 · 345 cases	None	Apr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections	0.828	No different	Oct 2024 – Sep 2025
MRSA BacteremiaInfections	0.742	No different	Oct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections	0	No different	Oct 2024 – Sep 2025
SSI - Colon SurgeryInfections	0.897	No different	Oct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits	14.5 · 200 cases	None	Jul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits	19.6 · 1,270 cases	None	Jul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits	31.2 · 189 cases	None	Jul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits	-6.1 · 1,115 cases	None	Jul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits	18.6 · 862 cases	None	Jul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits	17.7 · 949 cases	None	Jul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits	4.4 (3.1 to 6.5) · 349 cases	No different	Jan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits	9.6 (7.3 to 12.7) · 349 cases	No different	Jan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits	5.6 · 358 cases	None	Jul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits	11 · 165 cases	None	Jul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits	21.5 · 259 cases	None	Jul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits	11.2 (9.4 to 13.4) · 8,056 cases	No different	Jan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits	0.9 (0.7 to 1) · 1,959 cases	No different	Jan 2024 – Dec 2024

What patients said (2,820 patients answered, 23% of those asked)

Sort by

Patient survey stars by topic at Northwestern Memorial Hospital

Cleanliness	3
Nurse communication	4
Doctor communication	3
Communication about medicines	3
Discharge information	4
Overall hospital rating	4
Quietness	4
Recommend hospital	5

Sort by

Share of patients giving the best answer at Northwestern Memorial Hospital

Room was "always" clean	66%
Nurses "always" communicated well	79%
Doctors "always" communicated well	79%
Staff "always" explained	60%
Yes, staff "did" give patients this information	87%
Yes, staff "did" give patients information about help after discharge	85%
Doctors "always" explained things so they could understand	73%
Doctors "always" listened carefully	78%
Doctors "always" treated them with courtesy and respect	85%
Patients who gave a rating of "9" or "10" (high)	77%
Staff "always" explained new medications	74%
Nurses "always" explained things so they could understand	75%
Nurses "always" listened carefully	76%
Nurses "always" treated them with courtesy and respect	86%
"Always" quiet at night	63%
"YES", patients would definitely recommend the hospital	81%
Staff "always" explained possible side effects	45%
Yes, staff "did" give patients information about possible symptoms	89%

Original Medicare doctor bills

$1,323,422

Medicare paid this office $1,323,422 for 186 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	12	$347,093	None
Injection, denosumab, 1 mg	27	$129,000	None
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	12	$30,678	None
Administration of chemotherapy into vein, 1 hour or less	57	$18,811	$105
Return visit (30+ min)	51	$10,738	$100

See all 21 services

Sort by

Every Original Medicare service billed

Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	12	$347,093	None
Injection, denosumab, 1 mg	27	$129,000	None
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	12	$30,678	None
Administration of chemotherapy into vein, 1 hour or less	57	$18,811	$105
Return visit (30+ min)	51	$10,738	$100
Injection, fulvestrant, 25 mg	21	$6,519	None
New patient visit (60+ min)	31	$4,985	$161
Administration of additional new drug or substance into vein, 1 hour or less	21	$3,595	$52
Long return visit (40+ min)	22	$3,455	$138
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	32	$2,089	$23
Injection of additional new drug or substance into vein	38	$2,057	$13
Telephone medical discussion with physician, 11-20 minutes	13	$1,568	$75
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle	23	$1,528	$29
Injection, fosaprepitant, 1 mg	26	$1,220	None
Injection of drug or substance under skin or into muscle	39	$957	$12
Application of on-body injector for under skin injection	14	$672	$15
Injection, palonosetron hcl, 25 mcg	27	$612	None
Injection, paclitaxel, 1 mg	12	$310	None
Injection, dexamethasone sodium phosphate, 1 mg	30	$80	None
Injection, diphenhydramine hcl, up to 50 mg	15	$14	None
Unclassified drugs	14	$12	None

Who their Medicare patients are

186 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 7% · Also on Medicaid 18% · Health risk score 1.89. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.

Conditions among them: Cancer 75% · High blood pressure 63% · Diabetes 24% · Coronary heart disease 22% · Heart failure 20% · Chronic kidney disease 20% · Depression 18% · Atrial fibrillation 15% · COPD 13% · Stroke 8%.

The office billed $6,125,040, Medicare allowed $1,662,426 and paid $1,323,422; for 82,491 services of 78 kinds; $1,267,754 of it was for drugs given in the office and $55,667 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	186	82,491	73	1.89	$6,125,040	$1,323,422
2023	159	7,562	74	1.89	$594,512	$111,604
2022	158	357	73	1.69	$118,300	$26,763
2021	164	362	74	1.57	$162,502	$34,046
2020	177	401	74	2.20	$170,266	$33,580
2019	209	465	73	2.02	$151,140	$37,246
2018	220	531	72	1.93	$141,040	$39,319
2017	260	662	72	2.17	$188,300	$53,305
2016	186	757	72	2.05	$207,284	$51,817
2015	85	5,734	72	2.17	$924,664	$153,330
2014	144	783	71	1.81	$144,359	$42,566
2013	201	557	71	1.55	$116,480	$51,243

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 3 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	53	$5,456	$74
Administration of chemotherapy into vein, 1 hour or less	14	$2,748	$110
Short return visit (20+ min)	54	$2,442	$44

2022: 6 services

Sort by

Original Medicare services billed in 2022

Return visit (30+ min)	99	$11,936	$77
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	13	$4,867	$88
Long return visit (40+ min)	17	$2,487	$96
Short return visit (20+ min)	41	$2,288	$54
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	12	$1,786	$62
Hospital discharge day management, 30 minutes or less	16	$1,066	$63

2021: 3 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	63	$17,371	$116
Return visit (30+ min)	112	$11,828	$79
New patient visit (60+ min)	11	$1,766	$161

2020: 6 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	72	$12,303	$87
Return visit (30+ min)	80	$6,317	$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	24	$6,035	$86
Initial hospital care with moderate level of medical decision making at least 75 minutes	19	$3,322	$175
New patient visit (60+ min)	16	$2,280	$142
Telephone medical discussion with physician, 21-30 minutes	20	$1,427	$68

2019: 7 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	66	$12,530	$93
Return visit (30+ min)	101	$8,049	$60
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$7,741	$88
Initial hospital care with moderate level of medical decision making at least 75 minutes	22	$3,498	$159
New patient visit (60+ min)	20	$2,885	$144
Short return visit (20+ min)	29	$1,510	$42
Short return visit	18	$416	$20

2018: 6 services

Sort by

Original Medicare services billed in 2018

Return visit (30+ min)	153	$16,975	$62
Long return visit (40+ min)	28	$7,266	$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$6,120	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	19	$3,622	$172
Short return visit (20+ min)	40	$1,793	$43
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	13	$1,362	$62

2017: 6 services

Sort by

Original Medicare services billed in 2017

Return visit (30+ min)	169	$18,862	$63
Long return visit (40+ min)	56	$13,210	$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	42	$9,582	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	32	$5,511	$172
New patient visit (60+ min)	22	$3,081	$140
Short return visit (20+ min)	26	$1,090	$40

2016: 6 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	53	$12,448	$92
Return visit (30+ min)	109	$12,057	$62
Initial hospital care with moderate level of medical decision making at least 75 minutes	33	$6,180	$172
New patient visit (60+ min)	36	$5,027	$140
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	17	$3,612	$88
Short return visit (20+ min)	21	$997	$42

2015: 8 services

Sort by

Original Medicare services billed in 2015

Return visit (30+ min)	24	$8,977	$88
New patient visit (60+ min)	15	$2,618	$175
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	19	$2,192	$61
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	11	$2,108	$88
Short return visit (20+ min)	13	$1,499	$62
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	16	$529	$10
Insertion of needle into vein for collection of blood sample	16	$71	$3
Infusion, normal saline solution, 250 cc	11	$34	None

2014: 5 services

Sort by

Original Medicare services billed in 2014

Return visit (30+ min)	82	$13,468	$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	28	$7,501	$87
New patient visit (60+ min)	25	$4,280	$171
Initial hospital care with moderate level of medical decision making at least 75 minutes	17	$3,169	$176
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	11	$1,183	$62

2013: 6 services

Sort by

Original Medicare services billed in 2013

Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	52	$14,185	$89
Initial hospital care with moderate level of medical decision making at least 75 minutes	57	$10,257	$174
Short return visit (20+ min)	78	$7,885	$63
Return visit (30+ min)	57	$7,769	$91
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes	22	$4,944	$61
New patient visit (45+ min)	24	$3,547	$148

Medicaid work

$11,520 in 2024

Medicaid paid $11,520 for 218 billed services this clinician did in 2024, up to 19 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	155	$10,410
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	63	$1,110

Sort by

Medicaid work by year

2024	218	2	19	$11,520
2018	41	1	12	$1,184

See the largest Medicaid services in earlier years

2018

Sort by

Largest Medicaid services in 2018

SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES	41	$1,184

Drugs they prescribed that Part D paid

$189,345

Pharmacies billed $189,345 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 88) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.

72 generic and 16 brand-name prescriptions · $189,345 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Anastrozole	23	$949	$18

Year by year

Sort by

Part D prescribing by year

2024	88	36	0% (0)	18%	$189,345
2022	11	None	0% (0)	None	$29,476
2021	42	14	0% (0)	None	$54,693
2020	65	18	0% (0)	None	$66,941
2019	95	26	0% (0)	0%	$3,500
2018	140	44	None	None	$25,500
2017	63	25	None	None	$4,240
2016	95	38	None	16%	$85,849
2015	183	42	None	14%	$144,620
2014	245	87	None	9%	$31,108
2013	257	75	None	12%	$83,307

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2021: 1 drug

Sort by

Part D drugs prescribed in 2021

Anastrozole	18	$499	$28

2020: 1 drug

Sort by

Part D drugs prescribed in 2020

Anastrozole	37	$401	$11

2019: 2 drugs

Sort by

Part D drugs prescribed in 2019

Anastrozole	51	$904	$18
Letrozole	15	$194	$13

2018: 3 drugs

Sort by

Part D drugs prescribed in 2018

Exemestane	25	$11,191	$448
Anastrozole	65	$1,206	$19
Megestrol Acetate	15	$177	$12

2017: 1 drug

Sort by

Part D drugs prescribed in 2017

Anastrozole	30	$446	$15

2016: 1 drug

Sort by

Part D drugs prescribed in 2016

Anastrozole	38	$377	$10

2015: 4 drugs

Sort by

Part D drugs prescribed in 2015

Anastrozole	71	$1,142	$16
Tamoxifen Citrate	16	$397	$25
Letrozole	15	$113	$8
Dexamethasone	16	$112	$7

2014: 5 drugs

Sort by

Part D drugs prescribed in 2014

Exemestane	29	$17,507	$604
Raloxifene	11	$4,909	$446
Anastrozole	83	$2,351	$28
Tamoxifen Citrate	67	$2,028	$30
Letrozole	13	$1,132	$87

2013: 5 drugs

Sort by

Part D drugs prescribed in 2013

Exemestane	32	$15,490	$484
Evista	12	$4,800	$400
Anastrozole	81	$4,786	$59
Tamoxifen Citrate	59	$1,806	$31
Letrozole	22	$813	$37

Money from drug and device companies

$9,479 in 2025

Sort by

Industry payments by year

2025	4	11	$8,353	$9,479
2024	7	9	$685	$1,515
2023	4	9	$5,740	$6,291
2022	3	4	$1,500	$1,676
2021	5	7	$10,250	$10,262
2020	5	6	$9,465	$9,522
2019	5	8	None	$779

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

AstraZeneca Pharmaceuticals LP	Enhertu	$3,438	3 payments Consulting for Enhertu · 2025-12-22 · $2,460 Meals for Enhertu · 2025-12-11 · $135 Paid to speak or teach · 2025-02-14 · $843
Genentech USA	Itovebi	$3,169	4 payments Meals for Perjeta · 2025-08-20 · $109 Consulting for Itovebi · 2025-03-06 · $2,320 Travel for Itovebi · 2025-03-06 · $500 Meals for Itovebi · 2025-03-06 · $239
Stemline Therapeutics	Orserdu	$2,845	3 payments Meals for Orserdu · 2025-08-22 · $47 Consulting for Orserdu · 2025-08-22 · $2,730 Meals for Orserdu · 2025-08-22 · $68
Incyte	Jakafi	$28	1 payment Meals for Jakafi · 2025-03-11 · $28

See all 11 published payments

Sort by

Every published payment

AstraZeneca Pharmaceuticals LP	Consulting · 2025-12-22	Enhertu	$2,460
AstraZeneca Pharmaceuticals LP	Meals · 2025-12-11	Enhertu	$135
Stemline Therapeutics	Meals · 2025-08-22	Orserdu	$47
Stemline Therapeutics	Consulting · 2025-08-22	Orserdu	$2,730
Stemline Therapeutics	Meals · 2025-08-22	Orserdu	$68
Genentech USA	Meals · 2025-08-20	Perjeta	$109
Incyte	Meals · 2025-03-11	Jakafi	$28
Genentech USA	Consulting · 2025-03-06	Itovebi	$2,320
Genentech USA	Travel · 2025-03-06	Itovebi	$500
Genentech USA	Meals · 2025-03-06	Itovebi	$239
AstraZeneca Pharmaceuticals LP	Paid to speak or teach · 2025-02-14	None	$843

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $1,515

Sort by

Payments by company in 2024

AstraZeneca Pharmaceuticals LP	None	$895	3 payments Consulting · 2024-07-01 · $685 Meals · 2024-06-04 · $112 Meals · 2024-06-02 · $98
Genentech USA	None	$142	1 payment Meals · 2024-12-11 · $142
Gilead Sciences	Trodelvy	$131	1 payment Meals for Trodelvy · 2024-08-23 · $131
Pfizer	Ibrance	$131	1 payment Meals for Ibrance · 2024-08-23 · $131
Stemline Therapeutics	Orserdu	$97	1 payment Meals for Orserdu · 2024-08-24 · $97
Merck Sharp & Dohme	None	$96	1 payment Meals · 2024-12-13 · $96
Daiichi Sankyo	Vanflyta	$23	1 payment Meals for Vanflyta · 2024-07-19 · $23

2023: $6,291

Sort by

Payments by company in 2023

AstraZeneca Pharmaceuticals LP	Enhertu	$6,121	6 payments Consulting · 2023-12-18 · $2,740 Meals · 2023-12-06 · $135 Consulting · 2023-07-12 · $1,500 Consulting for Enhertu · 2023-07-03 · $1,500 Meals · 2023-06-05 · $135 Meals for Enhertu · 2023-01-21 · $111
Gilead Sciences	Trodelvy	$118	1 payment Meals for Trodelvy · 2023-12-09 · $118
Puma Biotechnology	None	$29	1 payment Meals · 2023-03-13 · $29
Astellas Pharma US	Cresemba	$23	1 payment Meals for Cresemba · 2023-10-04 · $23

2022: $1,676

Sort by

Payments by company in 2022

Seagen	Tukysa	$1,500	1 payment Consulting for Tukysa · 2022-03-25 · $1,500
Genentech USA	Kadcyla	$157	2 payments Meals · 2022-12-07 · $123 Meals for Kadcyla · 2022-01-22 · $34
Emmaus Medical	Endari	$19	1 payment Meals for Endari · 2022-02-02 · $19

2021: $10,262

Sort by

Payments by company in 2021

AstraZeneca UK	Lynparza	$4,750	3 payments Consulting for Lynparza · 2021-07-13 · $1,750 Consulting for Lynparza · 2021-07-13 · $1,500 Consulting for Lynparza · 2021-04-18 · $1,500
Genzyme	None	$2,500	1 payment Consulting · 2021-09-15 · $2,500
Pfizer	Ibrance	$2,000	1 payment Honoraria for Ibrance · 2021-05-14 · $2,000
Eli Lilly and	None	$1,000	1 payment Consulting · 2021-08-03 · $1,000
Gilead Sciences	None	$12	1 payment Education · 2021-06-01 · $12

2020: $9,522

Sort by

Payments by company in 2020

Daiichi Sankyo	Enhertu	$4,365	1 payment Consulting for Enhertu · 2020-01-21 · $4,365
Eli Lilly and	None	$3,750	2 payments Consulting · 2020-10-12 · $1,000 Consulting · 2020-09-09 · $2,750
Pfizer	None	$1,350	1 payment Consulting · 2020-06-16 · $1,350
Seagen	Tukysa	$35	1 payment Education for Tukysa · 2020-04-30 · $35
Dova Pharmaceuticals	Doptelet	$22	1 payment Meals for Doptelet · 2020-05-12 · $22

2019: $779

Sort by

Payments by company in 2019

Daiichi Sankyo	Enhertu	$476	4 payments Travel for Enhertu · 2019-08-20 · $295 Meals for Enhertu · 2019-07-28 · $90 Meals for Enhertu · 2019-07-28 · $62 Meals for Enhertu · 2019-07-28 · $30
AstraZeneca Pharmaceuticals LP	Lynparza	$125	1 payment Meals for Lynparza · 2019-08-28 · $125
Taiho Oncology	Lonsurf	$118	1 payment Meals for Lonsurf · 2019-11-15 · $118
Puma Biotechnology	Nerlynx	$36	1 payment Meals for Nerlynx · 2019-12-12 · $36
Pfizer	Inlyta	$24	1 payment Meals for Inlyta · 2019-08-30 · $24

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy · 2020	Their institution	$273,607
Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy · 2019	Their institution	$219,450
PFIZER INC. · Phase 1b Study To Assess the Safety Tolerability and Clinical Activity of Gedatolisib in Combination With Palbociclib and Either Letrozole Or Fulvestrant in Women With Metastatic Or Locally Advancedrecurrent Breast Cancer Mbc · 2019	Their institution	$191,609
Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy for Advanced Disease · 2021	Their institution	$154,893
Radius Health, Inc. · A Randomized, Multicenter, Phase 2 Study of Elacestrant (Rad1901) Versus Investigators Choice of Fulvestrant Or Aromatase Inhibitor Therapy for the Treatment of Postmenopausal Women With Er+/Her2- Breast Cancer · 2020	Their institution	$154,252
Novartis Pharmaceuticals Corporation · A Phase II Multicenter Open Label Two Cohort Non Comparative Study To Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant Or Letrozole in Patients With Pik3ca Mutant Hormone Receptor Hr Positive Her2 Negative Advanced Breast Cancer Abc Who Have P · 2020	Their institution	$122,644
Novartis Pharmaceuticals Corporation · A Phase II Multicenter Open Label Two Cohort Non Comparative Study To Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant Or Letrozole in Patients With Pik3ca Mutant Hormone Receptor Hr Positive Her2 Negative Advanced Breast Cancer Abc Who Have Progressed on Or After Cdk 4 6 Inhibitor Treatment · 2021	Their institution	$122,644
Stemline Therapeutics Inc. · Emerald: Phase 3 Trial of Elacestrant Vs. Standard of Care for the Treatment of Patients With Er+/Her2- Advanced Breast Cancer (Emerald) · 2022	Their institution	$69,283
Genentech, Inc. · Ipatasertib in Combination With Paclitaxel in Tnbc and Hr Breast Cancer · 2020	Their institution	$58,743
AstraZeneca Pharmaceuticals LP · A Randomised,Open Label,Phase III Study of Saruparib Azd5305 Plus Camizestrant Compared With Physicians Choice Cdk4 6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant for the First Line Treatment of Patients With Brca1,Brca2,Or Palb2 Mutations and Hormone Receptor Positive, Her2 Negative Ihc 0,1+,2+Ish Non-Amplified Advanced Breast Cancer Evopar Breast01 · 2025	Their institution	$49,540
Novartis Pharmaceuticals Corporation · A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Nab-Paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3- · 2022	Their institution	$44,683
Novartis Pharmaceuticals Corporation · A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Nab-Paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (Pik3ca) Mutation Or Phosphatase and Tensin Homolog Protein (Pten) Loss Without Pik3ca Mutation · 2021	Their institution	$41,103
PFIZER INC. · Phase 1b Study To Assess the Safety Tolerability and Clinical Activity of Gedatolisib in Combination With Palbociclib and Either Letrozole Or Fulvestrant in Women With Metastatic Or Locally Advancedrecurrent Breast Cancer Mbc · 2020	Their institution	$31,860
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Mk-3475 Plus Chemotherapy Vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer - Keynote-355 · 2019	Their institution	$29,448
Genentech, Inc. · 1l Mtnbc Ipatasertib Tecentriq Paclitaxel · 2020	Their institution	$28,575
Genentech, Inc. · Ipatasertib in Combination With Paclitaxel in Tnbc and Hr Breast Cancer · 2019	Their institution	$20,700
Genentech, Inc. · Palbociblib Fulvestrant Ipatasertib Ph3 Study in 1l Hr Her2 Mbc · 2020	Their institution	$19,485
Radius Health, Inc. · A Randomized, Multicenter, Phase 2 Study of Elacestrant Rad1901 Versus Investigator'S Choice of Fulvestrant Or Aromatase Inhibitor Therapy for the Treatment of Postmenopausal Women With Erher2- Breast Cancer · 2019	Their institution	$17,350
ABBVIE INC. · A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin To Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (Tnbc) · 2021	Their institution	$14,176
Radius Health, Inc. · A Randomized, Multicenter, Phase 2 Study of Elacestrant (Rad1901) Versus Investigators Choice of Fulvestrant Or Aromatase Inhibitor Therapy for the Treatment of Postmenopausal Women With Er+/Her2- Breast Cancer · 2021	Their institution	$14,160
Merck Sharp & Dohme Corporation · Outcomes Trial for Keytruda-Neoadjuvant Therapy in Patients With High-Risk Breast Cancer. · 2020	Their institution	$9,420
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Mk-3475 Plus Chemotherapy Vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Keynote-355 · 2022	Their institution	$8,498
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Mk-3475 Plus Chemotherapy Vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer Keynote-355 · 2021	Their institution	$8,368
Novartis Pharmaceuticals Corporation · A Phase II Multicenter Open Label Two Cohort Non Comparative Study To Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant Or Letrozole in Patients With Pik3ca Mutant Hormone Receptor Hr Positive Her2 Negative Advanced Breast Cancer Abc Who Have P · 2019	Their institution	$6,643
Novartis Pharmaceuticals Corporation · An Open Label Multicenter Phase Iiib Study of Ribociclib Lee011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive Hr Her2 Negative Her2 Advanced Breast Cancer Abc Who Received No Prior Hormonal Therapy · 2022	Their institution	$5,021
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Mk-3475 Plus Chemotherapy Vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer - Keynote-355 · 2020	Their institution	$4,362
Novartis Pharmaceuticals Corporation · A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Nab-Paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (Pik3ca) Mutation Or Phosphatase and Tensin Homolog Protein (Pten) Loss Without Pik3ca Mutation · 2023	Their institution	$3,311
Genentech, Inc. · Ipatasertib in Combination With Paclitaxel in Tnbc and Hr Breast Cancer · 2022	Their institution	$3,100
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2021	Their institution	$2,780
Genentech, Inc. · Ipatasertib in Combination With Paclitaxel in Tnbc and Hr Breast Cancer · 2021	Their institution	$2,600
Genentech, Inc. · Palbociblib Fulvestrant Ipatasertib Ph3 Study in 1l Hr Her2 Mbc · 2021	Their institution	$2,324
Novartis Pharmaceuticals Corporation · A Phase II Multicenter Open Label Two Cohort Non Comparative Study To Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant Or Letrozole in Patients With Pik3ca Mutant Hormone Receptor Hr Positive Her2 Negative Advanced Breast Cancer Abc Who Have Progressed on Or After Cdk 4 6 Inhibitor Treatment · 2023	Their institution	$1,750
F. Hoffmann-La Roche AG · An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult Patients With Advancedmetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib Rxdx-101 in Adult Patients With Locally Advanced Or Metastatic Cancer Confirmed To Be Positive for Ntrk1, Ntrk2, Nt · 2020	This clinician	$1,618
F. Hoffmann-La Roche AG · A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib Rxdx-101 in Children and Adolescents With Recurrent Or Refractory Solid Tumors and Primary Cns Tumors, With Or Without Trk, Ros1, Or Alk Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult P · 2019	This clinician	$1,272
PFIZER INC. · Oncology Portfolio Clinical Publication Program · 2020	This clinician	$1,270
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2019	Their institution	$860
Radius Health, Inc. · Nejm Emerald Manuscript · 2021	This clinician	$859
F. Hoffmann-La Roche AG · An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult Patients With Advancedmetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib Rxdx-101 in Adult Patients With Locally Advanced Or Metastatic Cancer Confirmed To Be Positive for Ntrk1, Ntrk2, Nt · 2019	This clinician	$850
PFIZER INC. · Prospective Observational Study of Mobile App Based Patient Reported Outcomes in Advanced Breast Cancer · 2020	Their institution	$750
PFIZER INC. · Prospective Observational Study of Mobile App Based Patient Reported Outcomes in Advanced Breast Cancer · 2019	Their institution	$750
Radius Health, Inc. · Emerald A Randomized, Open-Label, Phase 3 Trial To Evaluate the Efficacy and Safety of Elacestrant Rad1901, A Novel Oral Selective Estrogen Receptor Degrader Serd, Vs Investigators Choice of Endocrine Therapy for Erher2- Advanced Breast Cancer Following Cdk46 Inhibitor Therapy · 2019	Their institution	$708
Radius Health, Inc. · Sabcs Emerald Presentation · 2021	This clinician	$465
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2023	Their institution	$435
Eli Lilly and Company · Postmonarch: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study To Compare the Efficacy of Abemaciclib Plus Fulvestrant To Placebo Plus Fulvestrant in Participants With Hr+, Her2-, Advanced Or Metastatic Breast Cancer Following Progression on A Cdk4 & 6 Inhibitor and Endocrine Therapy · 2022	This clinician	$305
F. Hoffmann-La Roche AG · Phase 12, Open-Label, Dose-Escalation and Expansion Study of Entrectinib Rxdx-101 in Pediatrics With Locally Advanced Or Metastatic Solid Or Primary Cns Tumors Andor Who Have No Satisfactory Treatment Options, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult Patients Wit · 2020	This clinician	$266
Radius Health, Inc. · Sabcs Emerald Abstract · 2021	This clinician	$167
Merck Sharp & Dohme LLC · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2022	Their institution	$150
F. Hoffmann-La Roche AG · A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib Rxdx-101 in Children and Adolescents With Recurrent Or Refractory Solid Tumors and Primary Cns Tumors, With Or Without Trk, Ros1, Or Alk Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult · 2020	This clinician	$145
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Mk-3475 Plus Chemotherapy Vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable Or Metastatic Triple Negative Breast Cancer - Keynote-355 · 2025	Their institution	$117
Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2020	Their institution	$42
Eli Lilly and Company · Postmonarch: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study To Compare the Efficacy of Abemaciclib Plus Fulvestrant To Placebo Plus Fulvestrant in Participants With Hr+, Her2-, Advanced Or Metastatic Breast Cancer Following Progression on A Cdk4 & 6 Inhibitor and Endocrine Therapy · 2022	Their institution	$11

Professional record

NPI: 1568488526
Licence: CA C130396, IL 036164664California C130396: Current · expires 2027-09-30Illinois 036164664: Inactive
Group: Stanford Health Care
Video visits: Lists video visits
Gender: Female

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2006-07-14
NPI last updated: 2025-10-01
NPI record certified: 2025-10-01

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 250 E Superior St Ste 4-420, Chicago, IL, 60611 · 1441 Eastlake Ave, Los Angeles, CA, 90089

This office lists an electronic records connection.